---
title: 'Associate Director, Medical Marketing at Definium Therapeutics'
canonical: 'https://feeny.ai/job/associate-director-medical-marketing-definium-therapeutics-remote-eav95eymjzpf'
type: 'job'
last_seen: '2026-10-27'
---

# Associate Director, Medical Marketing at Definium Therapeutics

- **Company:** Definium Therapeutics
- **Location:** Remote
- **Compensation:** $170k–$198k
- **Work type:** remote
- **Posted:** 2026-10-14
- **Last confirmed live:** 2026-10-27
- **Apply:** https://job-boards.greenhouse.io/definiumtherapeutics/jobs/6223324004

## Job description

Definium Therapeutics is a late-stage clinical biopharmaceutical company and our mission is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale.

Our lead product candidate, lysergide tartrate (our proprietary orally disintegrating tablet form of lysergide (LSD) D-tartrate), represents a highly differentiated, potential best-in-class opportunity for patients suffering from generalized anxiety, major depressive disorder, and posttraumatic stress disorder. Our early stage pipeline includes DT402, the R-enantiomer of MDMA and is under development to target the core symptoms of autism spectrum disorder (ASD), specifically addressing social communication challenges.

Guided by the recognition that patients deserve more than better, Definium is relentlessly advancing a new generation of therapeutics intended to address the underlying causes of psychiatric and neurological disorders. By turning evidence into impact, Definium aims to change the trajectory of today’s mental health care crisis and enable a healthier future. Headquartered in New York, Definium Therapeutics trades on Nasdaq under the symbol DFTX.

Together we are moving psychiatry forward—beyond better, into a boundless future. Join us!

The Associate Director, Medical Marketing will support the development and execution of strategic medical marketing initiatives to drive the successful commercial launch of DT120, working closely with Medical Affairs, Regulatory, Commercial, Clinical Development, and cross-functional teams to align with corporate goals. This role will help shape scientific engagement strategy through KOL development, advisory boards, congress activities, and evidence communication initiatives, while ensuring all activities meet applicable regulatory and compliance standards.

## Responsibilities

- Develop and execute medical marketing initiatives that support the scientific positioning and successful commercialization of DT120
- Lead KOL engagement strategy, including identification, segmentation, relationship development, and ongoing engagement planning
- Manage advisory board planning and execution, including objectives, attendee selection, content development, logistics, and insight capture
- Support medical congress strategy and execution, including sponsorships, exhibits, symposia, scientific communications, and stakeholder engagement activities
- Partner with Medical Affairs, Clinical Development, Commercial, and Regulatory teams to align scientific engagement activities with broader organizational objectives
- Direct external agency partners and vendors supporting congresses, advisory boards, speaker programs, and scientific communications initiatives
- Gather and synthesize insights from KOL interactions, advisory boards, congresses, and market intelligence to inform brand and evidence-generation strategies
- Support development of scientific communication materials and engagement initiatives that strengthen awareness, credibility, and launch readiness

## Qualifications

- Bachelor's degree in Life Sciences, Marketing, Business, Communications, or related discipline; advanced degree preferred
- Minimum 8 years in the pharmaceutical, biotech, or healthcare industry, with experience in medical marketing, medical affairs operations, scientific communications, or commercial launch support
- Strong understanding of pharmaceutical regulations governing scientific exchange, promotional activities, and healthcare professional engagement
- Experience managing KOL engagement programs, advisory boards, and medical congress activities required
- Proven ability to lead initiatives and influence cross-functional teams in a matrixed environment
- Proficiency in analyzing scientific, clinical, and market insights to inform strategic decision-making
- Skilled in cross-functional collaboration; intellectually curious, solutions-oriented, and effective at communicating and socializing strategic recommendations
- Launch experience in the U.S. pharmaceutical market preferred
- Experience supporting scientific communications, congress planning, speaker programs, or publication-related activities preferred
- Experience in CNS / psychiatry, specialty pharmaceutical, or complex treatment categories preferred
- Experience with REMS products or novel treatment delivery models preferred
- Ability to synthesize complex clinical and market data into actionable strategies
- Strong presentation skills and ability to influence senior, cross-functional, KOL, and agency stakeholders
- Ability to travel as required; average 20–30%, with higher travel during congress and launch periods

Individual compensation within the range is determined based on factors such as relevant skills, experience, qualifications, scope of the role, and other legitimate business considerations.  In addition to base salary, this role may be eligible for bonus and equity opportunities. We also offer a comprehensive benefits package including health insurance, 401(k) with company match, flexible time off and additional wellness benefits and perks.  Learn more about our benefits on our Careers page.

The anticipated base salary range for this position is: $170,000—$198,000 USD

## About Definium Therapeutics

## Company Overview
- **One-liner**: Definium Therapeutics is a clinical-stage biopharmaceutical company applying scientific rigor to psychedelic medicine to develop accessible treatments for psychiatric disorders.
- **Entity Type**: Public (NASDAQ: DFTX)
- **Headquarters**: Not specified in available sources; the company operates as a remote-first organization.
- **Founded**: 2019 (originally as MindMed)
- **Founders**: Not publicly available in provided sources.

## Core Business
- **Primary Industry**: Biotechnology / Psychiatric drug development (psychedelic medicine)
- **Target Customers**: Patients with major depressive disorder (MDD), generalized anxiety disorder (GAD), posttraumatic stress disorder (PTSD), and autism spectrum disorder (ASD); also healthcare providers and payers.
- **Mission/Purpose**: “Unlock healing at scale” by harnessing the full therapeutic potential of psychedelic medicine through precise, evidence-based science.

## Products & Services
- **DT120 ODT (Lysergide/LSD D-Tartrate Oral Disintegrating Tablet)**: Investigational drug for GAD, MDD, and PTSD. Currently in four Phase 3 trials (Voyage, Panorama, Emerge, Ascend) and a fifth planned for PTSD. FDA Breakthrough Therapy Designation for GAD. No adjunctive psychotherapy required.
- **DT402 (R(-)-MDMA)**: R-enantiomer of MDMA selected for serotonergic properties with a potentially superior tolerability profile. In Phase 2a study for social communication challenges in autism spectrum disorder.

## Market Standing
- **Valuation/Market Cap**: Not publicly available (publicly listed on NASDAQ as DFTX as of 2026, but recent market cap not provided in search results).
- **Key Metric**: Pre-revenue clinical-stage company; total funding history not disclosed in available sources.
- **Notable Investors/Partners**: Not disclosed in provided sources.
- **Growth Signals**:
  - Five Phase 3 trials ongoing or planned for DT120 ODT.
  - FDA Breakthrough Therapy Designation for DT120 in GAD.
  - Phase 2a trial initiated for DT402 in ASD.
  - Full results from Phase 2b GAD trial published in JAMA (2025).
  - Strong intellectual property with issued patents covering formulation, manufacturing, and treatment.

## Competitive Advantages
- **Proprietary Formulations**: Pharmaceutically optimized ODT for LSD (DT120) and novel R-enantiomer of MDMA (DT402) with potential improved tolerability.
- **Scientific Rigor**: Standalone drug studies without psychotherapy, enabling clearer efficacy and safety data.
- **Regulatory Momentum**: FDA Breakthrough Therapy Designation and multiple IND clearances.
- **Experienced Management Team**: Proven track record in developing and commercializing CNS therapies.
- **Comprehensive IP Strategy**: Patents covering drug formulations, methods of manufacture, and treatment use.

## Strategic Focus
- **Late-Stage Pipeline Advancement**: Completing Phase 3 trials for GAD and MDD, initiating PTSD trial.
- **Pipeline Expansion**: Advancing DT402 for ASD and exploring additional neuropsychiatric indications.
- **Commercial Readiness**: Building infrastructure (hiring VP of Sales, Senior Director of Field VEOR, etc.) to support potential future launch.
- **Data Generation**: Generating high-quality evidence to support regulatory submissions and differentiation.

## Why Work Here
- **Remote-First Culture**: “You can live anywhere in the country you’re employed in” (remote-first workforce).
- **Comprehensive Benefits**: 100% paid medical, dental, vision for employees and dependents; FSA/HSA; life and disability insurance.
- **Wellness & Time Off**: Annual wellness allowance, flexible PTO, company-wide shutdowns for rest.
- **Family Support**: Paid parental leave for birthing and non-birthing parents, 2-week return-to-work transition.
- **Financial Wellness**: Competitive compensation, 401(k) with employer match, employee equity (new hire grants and refreshes), Employee Stock Purchase Plan (ESPP) with discount.
- **Mission-Driven Work**: Opportunity to contribute to groundbreaking treatments in psychedelic psychiatry with a science-driven, collaborative team.

## Sources
1. [definiumtx.com](https://definiumtx.com/) – Company overview and pipeline details
2. [definiumtx.com](https://definiumtx.com/story/) – Company history, leadership, and strategic milestones
3. [definiumtx.com](https://definiumtx.com/careers/) – Careers page with benefits and remote-first policy
4. [definiumtx.com](https://definiumtx.com/research-development/) – Research and development pipeline details
5. [linkedin.com](https://www.linkedin.com/company/definiumtherapeutics) – LinkedIn company page

## Other roles at Definium Therapeutics

- [Senior Clinical Trial Manager](https://feeny.ai/job/senior-clinical-trial-manager-definium-therapeutics-remote-wvrjhsw19grb)
- [Associate Director, Brand Counsel](https://feeny.ai/job/associate-director-brand-counsel-definium-therapeutics-remote-drzwb505czfs)
- [Director, Field Operations](https://feeny.ai/job/director-field-operations-definium-therapeutics-remote-03sqbsdm57aa)
- [Manager, Data & Analytics](https://feeny.ai/job/manager-data-analytics-definium-therapeutics-remote-1myd7q4ncfyq)
- [Sr. Director, Sales Training](https://feeny.ai/job/sr-director-sales-training-definium-therapeutics-remote-4e05xqacax1x)
- [Director, Regulatory Affairs (Advertising and Promotions)](https://feeny.ai/job/director-regulatory-affairs-advertising-and-promotions-definium-therapeutics-yttv1kff5hzj)
- [Associate Director, Statistical Programming](https://feeny.ai/job/associate-director-statistical-programming-definium-therapeutics-remote-32hes91t3fd9)
- [Director, Supply and Distribution Quality](https://feeny.ai/job/director-supply-and-distribution-quality-definium-therapeutics-remote-6hf75zdnx5pq)
- [Director, Medical Communications](https://feeny.ai/job/director-medical-communications-definium-therapeutics-remote-35fwkadvgv4y)
- [Director, Patient Services Operations](https://feeny.ai/job/director-patient-services-operations-definium-therapeutics-raleigh-durham-b25ndrr3vznf) — Raleigh/durham, NC